Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to launch ...

The company will offer up to 12.8 million shares of common stock that could fetch up to $57.5 million in gross proceeds. Today, Invitae announced that each share will be offered at $4.50, which is ...

Invitae’s (NVTA) significant revenue growth in its most recently reported quarter and its success in bringing customized health monitoring into the mainstream have heightened investor optimism around ...

Invitae's business has been growing rapidly and there's still more growth on the horizon. The beaten-up stock is a risky buy given its significant losses and persistent cash burn. Invitae is in the ...

As of the third quarter of 2023, Invitae had already tallied a net loss of more than $1.3 billion for the year, with cash burn of $311 million as of Sept. 30 and just under $265 million left in cash ...

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...

This week, Invitae put out a press release highlighting the insights Praxis Precision Medicines was getting from Invitae's Citizen platform. The platform enables companies to get medical history data ...

Invitae stock surged as much as 7% on Monday after a report out of the Wall Street Journal said Softbank plans to lead a $1.2 billion investment in the San Francisco-based genetic testing company. The ...

We recently compiled a list of the 10 Best Stocks to Buy and Hold For 5 Years According to Cathie Wood. In this article, we are going to take a look at where Invitae Corporation (OTC:NVTAQ) stands ...

Invitae (NYSE: NVTA) shares have plummeted more than 80% this year. The genetic testing company has grown revenue over the years, but it hasn't been able to turn that revenue into profit. Instead, ...